Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Phase 1
9(100.0%)
9Total
Phase 1(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT03913949Phase 1Active Not Recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Role: collaborator

NCT04501120Phase 1Recruiting

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Role: collaborator

NCT06182969Phase 1Recruiting

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Role: collaborator

NCT04001777Phase 1Active Not Recruiting

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Role: collaborator

NCT03917043Phase 1Recruiting

APG-2449 in Patients With Advanced Solid Tumors

Role: collaborator

NCT04785196Phase 1Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Role: collaborator

NCT05701306Phase 1Recruiting

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Role: collaborator

NCT04275518Phase 1Recruiting

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Role: collaborator

NCT03387332Phase 1Terminated

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Role: collaborator

All 9 trials loaded